Exenatide

What it is

The Bydureon BCise label identifies exenatide as a 39-amino-acid synthetic peptide amide. AC2993 is a development identifier. Byetta is an immediate-release product; Bydureon and Bydureon BCise are extended-release products. These product names do not describe one interchangeable formulation.

Immediate-release injection, extended-release microsphere formulations, devices, excipients, release profiles, approved populations, and warning sets differ. A generic referencing Byetta does not become equivalent to Bydureon BCise, and an approved exenatide record does not authenticate a compounded or unidentified product.

Why people care

Exenatide was the first FDA-approved GLP-1 receptor agonist and has large cardiovascular-safety and glycemic trial records. Reader confusion now centers on whether approval equals current branded availability, whether immediate- and extended-release products are interchangeable, and whether a diabetes indication establishes a weight-management indication.

What humans actually show

Exenatide is an FDA-approved GLP-1 receptor agonist active ingredient for defined type 2 diabetes uses. Formulation and marketing status matter: FDA records document permanent discontinuation of the branded immediate- and extended-release products, while a generic abbreviated application has Prescription marketing status. Evidence from an extended-release product cannot automatically be transferred to an immediate-release generic, another formulation, or a general weight-loss claim.

• approved label — Adults and pediatric patients with type 2 diabetes in product-specific immediate- or extended-release programs; Route: Subcutaneous, using the product-specific formulation; Outcome: Glycemic control: FDA records support defined type 2 diabetes indications. The 2025 FDA review states that immediate-release Byetta was indicated for adults, while extended-release Bydureon and Bydureon BCise had pediatric labeling for patients aged 10 years and older. The seam: The indication and age boundary depend on the exact product; The branded products have discontinuation records; The approved uses are not general weight-management indications; Product-specific evidence cannot be transferred across formulations without support.
• randomized human — 14,752 adults with type 2 diabetes, with or without previous cardiovascular disease; Route: Weekly subcutaneous extended-release exenatide or matching placebo added to usual care; Outcome: First cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke over a median 3.2 years: Extended-release exenatide was noninferior to placebo for cardiovascular safety but was not superior for the primary composite outcome. The seam: The trial used an extended-release product, not the current immediate-release generic record; The population had type 2 diabetes; Noninferiority for cardiovascular safety is not proof of cardiovascular benefit; The result does not establish a weight-management indication.
• randomized human — 83 participants aged 10 to under 18 years with type 2 diabetes suboptimally controlled with current treatments; Route: Weekly subcutaneous extended-release exenatide or placebo for 24 weeks; Outcome: Change in glycated hemoglobin, other metabolic outcomes, and adverse events: The study reported a greater glycated-hemoglobin reduction with exenatide than placebo. Between-group differences in body weight and several secondary measures were not statistically significant. The seam: Small pediatric trial with a 24-week controlled period; The formulation was extended-release and the finding cannot be transferred to immediate-release generic exenatide; The study addressed type 2 diabetes, not general pediatric weight management; The study did not establish a body-weight outcome.

Mechanistic and nonhuman evidence

• mechanistic — Labeled pharmacology record; Route: Subcutaneous labeled exenatide product; Outcome: GLP-1 receptor activation, glucose-dependent insulin secretion, glucagon secretion, and gastric emptying: The extended-release label describes glucose-dependent insulin release, suppression of inappropriately elevated glucagon secretion, and slowed gastric emptying. The seam: A mechanism does not establish an unapproved clinical use; Mechanistic class similarity does not make products interchangeable; Slowed gastric emptying creates interaction and procedural-safety boundaries.
• animal — Rat studies summarized in the extended-release product label; Route: Extended-release exenatide exposure in animals; Outcome: Thyroid C-cell tumors: The Bydureon BCise label reports an increased incidence of thyroid C-cell tumors in rats and states that the human relevance is unknown. The seam: The boxed warning is specific to the extended-release product label; Animal findings do not quantify human risk; The record does not establish efficacy or transfer every warning to every formulation by inference.

FDA and U.S. status

FDA approval records exist for immediate- and extended-release exenatide products for defined type 2 diabetes uses, and Drugs@FDA records the first generic referencing Byetta as approved on November 19, 2024. FDA's April 2025 pharmacovigilance review records permanent-discontinuation notices for Byetta and Bydureon BCise and a March 2021 permanent withdrawal from sale for Bydureon. The openFDA exact-substance record, last updated July 28, 2026, lists the Byetta products as Discontinued and ANDA206697 exenatide products as Prescription. Approval, branded marketing status, formulation, and current practical availability are separate questions.

Risks and warning limits

• approved label: The extended-release Bydureon BCise label carries a boxed warning for thyroid C-cell tumors observed in rats and contraindicates use with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The warning set is formulation-specific and should not be silently transferred to another product.
• approved label: FDA's product-specific label summaries include acute pancreatitis, hypoglycemia with insulin secretagogues or insulin, acute kidney injury, severe gastrointestinal disease, immunogenicity, serious hypersensitivity, drug-induced immune-mediated thrombocytopenia with potentially fatal bleeding, gallbladder disease, and pulmonary aspiration. Extended-release labeling also includes serious injection-site reactions.
• human trial: Common adverse reactions differ by formulation. FDA's review lists gastrointestinal and other reactions for immediate-release Byetta; the extended-release label identifies injection-site nodules and nausea among the most common reactions.

What remains unknown

• Current retail availability cannot be established from approval alone; the cited FDA records separate discontinued branded products from a generic application with Prescription marketing status.
• The cited evidence does not establish exenatide as an FDA-approved general weight-management treatment.
• The identity, release profile, sterility, potency, stability, and excipient profile of a compounded or unidentified exenatide product cannot be inferred from the active-ingredient name.

Product identity and quality limits

• Immediate-release Byetta-type exenatide and extended-release Bydureon-type exenatide have different formulations, release profiles, approved populations, and warning sets.
• The approved generic references Byetta; it does not make extended-release trial results or labeling automatically applicable to the generic product.
• Compounded drugs are not FDA approved, and an exenatide name cannot authenticate another formulation or product.

What has been studied together

• Extended-release exenatide with another exenatide-containing product — duplicate pathway overlap: The Bydureon BCise label states that it should not be used with other exenatide-containing products. This is a product-label prohibition, not a general rule inferred for every GLP-1 combination.
• Exenatide with insulin secretagogues, insulin, warfarin, or orally administered medicines — known label boundary: Product labeling records increased hypoglycemia risk with insulin secretagogues or insulin, postmarketing INR increases with warfarin, and possible delayed absorption of oral medicines because of slowed gastric emptying. These are specific monitoring and risk boundaries, not broad compatibility clearance.

What people are hearing

These are claims this profile checks, not established conclusions.

• Claim under review: “Every exenatide formulation has the same indication, warnings, and human evidence.”
• Claim under review: “An FDA approval record proves that the branded Byetta or Bydureon product is currently marketed.”
• Claim under review: “Exenatide's diabetes evidence makes it an FDA-approved general weight-loss drug.”

Questions readers raise

• No reproducible community sample was collected for this profile.

The community-signal layer is not efficacy or safety evidence. Its current limits are:

• No reproducible community sample has been collected for this profile.
• Self-reports would be subject to selection and reporting bias.
• A report may not distinguish immediate-release, extended-release, generic, compounded, or unidentified exenatide.
• Concurrent medicines, health conditions, diet, and behavior could confound an anecdote.
• Reported outcomes could not be independently verified.
• Anecdotes cannot establish efficacy, safety, approval, product identity, availability, or interaction compatibility.

What would change this answer

• A new FDA marketing-status record, approval action, withdrawal action, or revised label would change the exact United States product boundary.
• Product-specific controlled trials would be required before transferring an outcome from an extended-release formulation to an immediate-release generic or another formulation.
• Product-specific analytical and manufacturing evidence would be required to assess an unidentified material.

Sources and records

• WADA — 2026 Prohibited List

• Exenatide Pediatric Postmarketing Pharmacovigilance Review, April 14, 2025 — U.S. Food and Drug Administration
• BYDUREON BCISE (exenatide extended-release) prescribing information, revised November 2024 — U.S. Food and Drug Administration
• Drugs@FDA API exact active-ingredient search for exenatide — U.S. Food and Drug Administration
• Drugs@FDA application record for ANDA206697, exenatide — U.S. Food and Drug Administration
• Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration
• ClinicalTrials.gov intervention search for exenatide — ClinicalTrials.gov
• PubMed search for exenatide in human records — National Library of Medicine
• Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes — PubMed
• EXSCEL trial registry record — ClinicalTrials.gov
• Once-Weekly Exenatide in Youth With Type 2 Diabetes — PubMed
• Pediatric extended-release exenatide trial registry record — ClinicalTrials.gov